SAN FRANCISCO, Nov. 14 – Myriad Genetics will market its predictive medicine products in Brazil through Sao Paulo-based Fleury Laboratories, the companies announced Wednesday.
The initial products marketed in Brazil from the Salt Lake City-based company will be cancer prediction kits, including ones to detect mutations for types of breast, skin, and colon cancer.
Financial details of the agreement were not disclosed.
Fleury Laboratories has 1,300 employees and 15 clinics throughout Brazil, according to the company.
Earlier in the month, Myriad reported a 22 percent rise in its revenue for the first quarter , from $10.8 million for the first quarter in 2000 to $13.2 million in 2001.